Related Experiment Video
Updated: Oct 4, 2025
The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits
Published on: August 20, 2014
A Sorbent with Synthetic Ligand for Removing Pro-atherogenic and Pro-inflammatory Components from Human Blood Plasma
O A Dmitrieva1, E D Ovchinnikova1, E A Utkina1
1Federal State Budgetary Institution «National Medical Research Center of Cardiology» Ministry of Health of the Russian Federation, Moscow, 121552 Russia.
Insights
A novel sorbent effectively removes C-reactive protein (CRP) and atherogenic lipoproteins from blood, offering a new treatment for cardiovascular diseases (CVD) and refractory hyperlipidemia. This approach targets key inflammatory and lipid markers associated with CVD.
Area of Science:
- Biomedical Engineering
- Cardiovascular Research
- Materials Science
Background:
- Cardiovascular diseases (CVD) are frequently associated with elevated levels of apolipoprotein B-100 (apoB-100) lipoproteins and systemic inflammation markers.
- Current treatments include pharmacotherapy and extracorporeal methods to reduce these concentrations.
Purpose of the Study:
- To evaluate the efficacy and selectivity of a newly designed sorbent for removing C-reactive protein (CRP) and atherogenic lipoproteins.
- To assess the sorbent's potential for treating conditions like refractory hyperlipidemia and CVD with elevated CRP.
Main Methods:
- The study involved designing and testing a sorbent capable of removing both CRP and atherogenic lipoproteins.
- Key parameters such as desorption constants (Kd) for CRP and LDL, and distribution coefficients (Kc) for CRP and Lp(a) were calculated.
- The sorbent's capacity for binding atherogenic lipoproteins was quantified (up to 32 mg of total cholesterol (TC) per mL of sorbent gel).
Main Results:
- The sorbent demonstrated effective removal of both CRP and atherogenic lipoproteins from blood plasma.
- Calculated desorption constants indicated specific binding affinities: Kd for CRP was 4.2 × 10-8 M and for LDL was 7.7 × 10-7 M.
- Distribution coefficients were Kc = 101 for CRP and Kc = 38 for Lp(a), with a high binding capacity for lipoproteins.
Conclusions:
- The designed sorbent exhibits significant efficacy and selectivity in removing CRP and atherogenic lipoproteins.
- It shows promise as a therapeutic option for complex removal of these components in patients with refractory hyperlipidemia and CVD.
- This sorbent offers a potential adjunctive therapy for managing cardiovascular risk factors.
Abstract:
Elevated levels of apoB-100 containing lipoproteins and markers of systemic inflammation are often observed in patients with cardiovascular diseases. The concentrations can be reduced by pharmacotherapy or extracorporeal treatment. The sorbent, which removes CRP and atherogenic lipoproteins, simultaneously reduces the bloodstream concentration of these components. The efficacy and selectivity of the designed sorbent were studied, desorption constants of CRP (Kd = 4.2 × 10-8 M) and LDL (Kd = 7.7 × 10-7 M) were distribution coefficients of CRP (Kc = 101) and Lp(a) (Kc = 38) were calculated, and the ability to bind large amounts of atherogenic lipoproteins (up to 32 mg of TC per mL of the sorbent gel) was demonstrated. Our sorbent can be recommended for performing complex removal of CRP and atherogenic lipoproteins from the blood plasma in patients with refractory hyperlipidemia and CVD that are accompanied by elevated levels of CRP.
More Related Videos
Related Concept Videos
01:30Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
01:29Drug Distribution: Plasma Protein Binding